...
search icon
vivs-img

VivoSim Labs, Inc., Common Stock

VIVS

NAQ

$2

+$0.03

(1.52%)

1D

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.35M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
169.51K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.56 L
$21.96 H
$2

About VivoSim Labs, Inc., Common Stock

VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California. more

Returns

Data is not properly formatted.

Financials

Mar '21Mar '22Mar '23Mar '24
Total Revenue-1.50M370.00K109.00K[{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":24.67,"profit":true},{"date":"2024-03-31","value":7.27,"profit":true}]
Cost of Revenue----[{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Gross Profit----[{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Gross Margin----[{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Operating Expenses16.83M12.98M18.10M15.20M[{"date":"2021-03-31","value":92.96,"profit":true},{"date":"2022-03-31","value":71.7,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":83.95,"profit":true}]
Operating Income(16.83M)(11.48M)(17.73M)(15.09M)[{"date":"2021-03-31","value":-1682600000,"profit":false},{"date":"2022-03-31","value":-1147900000,"profit":false},{"date":"2023-03-31","value":-1773100000,"profit":false},{"date":"2024-03-31","value":-1508600000,"profit":false}]
Total Non-Operating Income/Expense2.00K33.00K474.00K417.00K[{"date":"2021-03-31","value":0.42,"profit":true},{"date":"2022-03-31","value":6.96,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":87.97,"profit":true}]
Pre-Tax Income(16.82M)(11.45M)(17.26M)(14.67M)[{"date":"2021-03-31","value":-1682400000,"profit":false},{"date":"2022-03-31","value":-1144600000,"profit":false},{"date":"2023-03-31","value":-1725700000,"profit":false},{"date":"2024-03-31","value":-1466900000,"profit":false}]
Income Taxes----[{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Income After Taxes----[{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Income From Continuous Operations(16.83M)(11.45M)(17.26M)(14.67M)[{"date":"2021-03-31","value":-1682600000,"profit":false},{"date":"2022-03-31","value":-1144800000,"profit":false},{"date":"2023-03-31","value":-1725900000,"profit":false},{"date":"2024-03-31","value":-1467100000,"profit":false}]
Income From Discontinued Operations----[{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Net Income(16.83M)(11.45M)(17.26M)(14.67M)[{"date":"2021-03-31","value":-1682600000,"profit":false},{"date":"2022-03-31","value":-1144800000,"profit":false},{"date":"2023-03-31","value":-1725900000,"profit":false},{"date":"2024-03-31","value":-1467100000,"profit":false}]
EPS (Diluted)(29.43)(15.78)(23.77)(19.41)[{"date":"2021-03-31","value":-2943.37,"profit":false},{"date":"2022-03-31","value":-1578.23,"profit":false},{"date":"2023-03-31","value":-2376.64,"profit":false},{"date":"2024-03-31","value":-1941.25,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VIVS
Current Ratio 0.72
Quick Ratio 0.72

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VIVS
ROA (LTM) 0.00%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VIVS
Debt Ratio Lower is generally better. Negative is bad. 0.91
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.09

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VIVS
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.00
EV/R 0.00
EV/Ebitda NM

FAQs

What is VivoSim Labs, Inc. share price today?

VivoSim Labs, Inc. (VIVS) share price today is $2

Can Indians buy VivoSim Labs, Inc. shares?

Yes, Indians can buy shares of VivoSim Labs, Inc. (VIVS) on Vested. To buy VivoSim Labs, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VIVS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of VivoSim Labs, Inc. be purchased?

Yes, you can purchase fractional shares of VivoSim Labs, Inc. (VIVS) via the Vested app. You can start investing in VivoSim Labs, Inc. (VIVS) with a minimum investment of $1.

How to invest in VivoSim Labs, Inc. shares from India?

You can invest in shares of VivoSim Labs, Inc. (VIVS) via Vested in three simple steps:

  • Click on Sign Up or Invest in VIVS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in VivoSim Labs, Inc. shares
What is VivoSim Labs, Inc. 52-week high and low stock price?

The 52-week high price of VivoSim Labs, Inc. (VIVS) is $21.96. The 52-week low price of VivoSim Labs, Inc. (VIVS) is $1.56.

What is VivoSim Labs, Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of VivoSim Labs, Inc. (VIVS) is 0.00

What is the Market Cap of VivoSim Labs, Inc.?

The market capitalization of VivoSim Labs, Inc. (VIVS) is $3.35M

What is VivoSim Labs, Inc.’s stock symbol?

The stock symbol (or ticker) of VivoSim Labs, Inc. is VIVS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top